The South Gauteng High Court in Johannesburg has certified the first class action in South African history for sick workers, allowing gold miners suffering from silicosis and tuberculosis to proceed with their claims against 30 gold producers. Obstacles remain before sick miners receive compensation but this is an important victory for them.

New World Health Organization recommendations aim to speed up detection and improve treatment outcomes for multidrug-resistant TB through use of a novel rapid diagnostic test and a shorter, cheaper treatment regimen.

TB Europe Coalition released a position paper with recommendations for stakeholders in countries in Eastern Europe and Central Asia (EECA) to ensure a sustainable and responsible transition from donor support, and continued scale up of TB and HIV activities.

Linezolid is a critical component of regimens used to treat multidrug-resistant tuberculosis (MDR-TB). The GDF-negotiated price reduction is projected to save up to US$ 30 million over the next three years, helping to further improve equitable access to MDR-TB treatment.

Médecins Sans Frontières (MSF) released a report that outlines shortcomings of the current system for new drug development. The report highlights resulting access barriers and proposes policy solutions.

Advocates denounced the global response to an MDR-TB outbreak in Papua New Guinea and urged international agencies to immediately intervene.

The Zero Draft 2016 Political Declaration released ahead of the United Nations High-Level Meeting on Ending AIDS contains ambitious commitments to put the world on track to end AIDS and TB by 2030.

The TB Europe Coalition launched a guide for civil society organisations across the European region explaining how to access European Union (EU) funding to support their TB and HIV activities.

The Indian Ministry of Health and Family Welfare released Guidelines for use of Bedaquiline in RNTCP through conditional access under Programmatic Management of Drug Resistant Tuberculosis in India.

Stage 2 of trial aims to reduce MDR-TB treatment from 24 months to 6 or 9 months.